AVENUE – Sponsored by Hoffman-La RocheCompleted Study | Duration: 36 weeks
RO6867461 was a multi-center, prospective, and randomized Phase II clinical trial for the treatment of wet Age-Related Macular Degeneration (wet AMD). It compared the efficacy of intravitreal RO6867461 at different doses vs. intravitreal Lucentis® (ranibizumab). RO6867461 is a new drug with bispecific anti-VEGF and anti-angiopoietin-2 properties. Like VEGF, Angiopoietin-2 (Ang-2) is a key growth factor in the formation of blood vessels. RO6867461 targets both proteins simultaneously to better control new blood vessel formation associated with wet AMD. This trial was for patients with newly diagnosed wet AMD who had received no prior anti-VEGF treatment. Participants were treated and followed for 36 weeks.